Daniel P. Petrylak, MD, on immunotherapy & chemotherapy combinations in metastatic bladder cancer OBRoncology 0:58 6 years ago 22 Далее Скачать
Dr. Petrylak on Novel Immunotherapy Research in Bladder Cancer OncLive 1:01 8 years ago 204 Далее Скачать
Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer OncLive 0:38 7 years ago 154 Далее Скачать
Daniel Petrylak, MD, shares potential efficacy when adding immunotherapy such as sip-T in mCRPC OBRoncology 0:58 4 years ago 10 Далее Скачать
Dr. Daniel Petrylak Describes the Clinical Investigation of PROSTVAC in Prostate Cancer OncLive 0:47 11 years ago 265 Далее Скачать
Dr. Petrylak on Combinations with Pembrolizumab in Urothelial Carcinoma OncLive 1:05 7 years ago 68 Далее Скачать
Dr. Petrylak on Ongoing Investigations of Checkpoint Inhibition in Bladder Cancer OncLive 0:56 7 years ago 40 Далее Скачать
Dr. Daniel Petrylak Explains the Correlation Between Immune Response to Sipuleucel-T and Survival OncLive 1:08 12 years ago 355 Далее Скачать
Immunotherapy for Castration Resistant Prostate Cancer Grand Rounds in Urology 2:58 6 years ago 246 Далее Скачать
Daniel P. Petrylak, MD, regarding PD-L1 biomarkers in the treatment of bladder cancer OBRoncology 0:51 6 years ago 64 Далее Скачать
Dr. Petrylak on FDA Approval of Nivolumab in Bladder Cancer OncLive 0:37 7 years ago 244 Далее Скачать
Dr. Petrylak on Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma OncLive 2:03 5 years ago 306 Далее Скачать
Bladder Cancer: Immunotherapy in the Perioperative Setting OncLive 4:52 7 years ago 283 Далее Скачать
